Success Stories: With the Aid of the NIW PP Upgrade, a Research Specialist Pursuing a Career in Biostatistics Obtains NIW Approval in Just 5 Days
Client’s Testimonial:
“Retaining the Chen group for my NIW case was one of the greatest choices I've ever made. Above all, the outstanding service and professionalism from my attorney and the entire Chen law group stand out! As soon as I finished reading the petition letter, I was confident we were on the "green" path. Keep up the good work! Wishing everyone the best of luck!”
On January 31st, 2024, we received another EB-2 NIW (National Interest Waiver) approval for a Research Specialist in the Field of Biostatistics (Approval Notice).
General Field: Biostatistics
Position at the Time of Case Filing: Research Specialist
Country of Origin: China
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: January 31st, 2024
Processing Time: 5 days (Premium Processing Requested)
Case Summary:
We started compiling the most relevant, persuasive, and trustworthy information to persuade USCIS that the petitioner had satisfied the preponderance of the evidence when our client hired the North America Immigration Law Group to help him prepare his EB-2 NIW (National Interest Waiver) petition. We updated his petition package with the following details because we know how difficult it can be to navigate the complexity of an EB-2 NIW application, particularly when trying to meet the strict requirements set by immigration authorities:
Firstly, we submitted his M.S. in applied economics after examining his research and educational background. This demonstrated his ability to further his work on improving advanced biostatistical techniques for cardiovascular disease clinical trials to support better treatment protocols, patient outcomes, and healthcare policies.
In addition, we noted that his research in the field of biostatistics has resulted in 22 peer-reviewed journal articles. His works have been published in no fewer than 7 highly ranked peer-reviewed journals, accumulating 132 citations by other established researchers in the field worldwide, demonstrating the high regard and reliance placed on his work in the field.
Furthermore, his study has received funding from Cytokinetics; AstraZeneca; Novartis. This funding supports projects that promote science as a tool to transform healthcare. Therefore, his research clearly emphasizes the importance of overcoming challenges in heart failure management.
Based on the evidence we submitted, we convinced USCIS of our client's research, which has broad implications for the United States. Clinical trials are a crucial part of the U.S. healthcare system, contributing significantly to medical research and patient care. Creating robust clinical trials for treatment is essential, and our client's success in this field is imperative. With his extensive experience, the U.S. can develop advanced protocols and policies using enhanced biostatistical techniques. This not only ensures the quality of the U.S. healthcare system but also provides Americans with more viable treatment options, leading to better patient outcomes. We congratulate our client on receiving NIW approval and wish him further success in this amazing development.